Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.
-
Health officials are working to contain a new Ebola outbreak in the Democratic Republic of Congo. There's no approved vaccine for the strain of the virus that's spreading. -
After a tumultuous 13 months at the helm of the U.S. Food and Drug Administration, Marty Makary has resigned.
-
The resignation ends Dr. Marty Makary's management of the Food and Drug Administration, which was marked by turmoil and controversy. -
When the Food and Drug Administration approved Gleevec to treat a form of leukemia in 2001, it ushered in a new era in cancer care. -
Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a drug discount website. -
Insurance coverage of blockbuster obesity drugs has been spotty at best over the years, and it looks like things are getting worse, not better. Plans are dropping coverage or restricting it further.
-
The daily pill called Foundayo got a fast track through the Food and Drug Administration. It will compete with the pill form of Wegovy as an alternative to obesity drugs given by injection. -
In February, TrumpRx joined a growing list of websites consumers can tap for discounts on their medicines. Here's a cheat sheet for getting the best deal. -
A study in The Lancet finds that pregnant women in emergency rooms used less Tylenol after President Trump said it could raise their babies' risk of autism. Scientists say there is no proven link.
